Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
SYNEOS HEALTH, INC. |
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 42.98 USD | +0.02% | +0.49% | +17.18% | |
| Oct. 03 | Syneos Health Names Colin Shannon CEO | MT |
| Oct. 03 | Syneos Health, Inc. Announces Chief Executive Officer Changes | CI |
ETFs positioned on Syneos Health, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.91% | 3 M€ | +10.73% | - | |
| 3.46% | 430 M€ | -2.11% | - | |
| 1.62% | 219 M€ | +16.16% | ||
| 0.82% | 7 M€ | -9.86% | ||
| 0.77% | 2 M€ | -12.05% | ||
| 0.71% | 909 M€ | -7.18% | - | |
| 0.50% | 0 M€ | -.--% | - | |
| 0.42% | 329 M€ | -8.47% | ||
| 0.42% | 34 M€ | -3.97% | - | |
| 0.42% | 15 M€ | -5.31% | ||
| 0.42% | 6,059 M€ | -5.66% | ||
| 0.40% | 681 M€ | +6.91% | - | |
| 0.39% | 5,872 M€ | +5.37% | - | |
| 0.39% | 1,862 M€ | +5.52% | ||
| 0.39% | 9 M€ | +1.93% | ||
| 0.36% | 0 M€ | -.--% | - | |
| 0.29% | 10 M€ | +6.26% | ||
| 0.26% | 28 M€ | +9.03% | ||
| 0.26% | 3 M€ | +7.77% | - | |
| 0.26% | 8 M€ | +2.36% | - | |
| 0.26% | 132 M€ | -.--% | - | |
| 0.25% | 627 M€ | +9.21% | - | |
| 0.24% | 479 M€ | +13.70% | - | |
| 0.24% | 320 M€ | +4.84% | - | |
| 0.23% | 27 M€ | +25.70% | - | |
| 0.22% | 227 M€ | +8.35% | ||
| 0.19% | 1 M€ | +0.46% | ||
| 0.19% | 149 M€ | +8.90% | ||
| 0.19% | 6 M€ | -.--% | ||
| 0.19% | 1,458 M€ | +7.50% | ||
| 0.19% | 6,107 M€ | +7.72% | - | |
| 0.19% | 62,343 M€ | +7.70% | ||
| 0.19% | 137 M€ | +11.50% | - | |
| 0.19% | 3 M€ | 0.00% | - | |
| 0.19% | 101 M€ | +8.69% | - | |
| 0.19% | 73 M€ | +7.52% | - | |
| 0.19% | 1,389 M€ | +7.93% | - | |
| 0.19% | 16,365 M€ | +7.67% | - |
Syneos Health, Inc. is a biopharmaceutical solutions company that utilizes outsourced clinical drug development and commercialization services. The Company operates through two business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. The Clinical Solutions segment offers individual services including product development, project management, protocol development, investigational site recruitment, and clinical monitoring. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions (public relations, advertising, and medical communications), and consulting services. The Company's customers include small, mid-sized, and large companies in the biopharmaceutical, biotechnology, and medical device industries.
Calendar
2024-02-14
- Q4 2023 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +17.18% | 4 458 M $ | |
| +67.92% | 40 713 M $ | |
| +5.22% | 39 345 M $ | |
| -55.13% | 30 731 M $ | |
| -27.34% | 28 435 M $ | |
| +38.19% | 22 100 M $ | |
| -26.35% | 21 964 M $ | |
| -0.25% | 16 910 M $ | |
| -13.70% | 11 278 M $ | |
| -20.32% | 10 444 M $ |
- Stock
- Equities
- Stock Syneos Health, Inc. - Nyse
- Funds and ETFs Syneos Health, Inc.
